PATENT CLAIM ANALYSIS

Application Number: 16020688
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "267000"]

Abstract:
The present invention provides, inter alia, compounds capable of inhibiting NF-κB. Pharmaceutical compositions containing and methods of using the compounds are also provided herein. Also provided are methods and kits for treating cancer and solid tumors in a subject, as well as methods and kits for inducing cancer cell death and apoptosis of a cancer cell, all utilizing the NF-κB inhibitors described herein.

Claim (Index 1):
A method for treating cancer in a subject, comprising administering to the subject an effective amount of a compound having the structure of formula (I): wherein:\n A, B, C, and D are independently selected from the group consisting of carbon and nitrogen; \n X, Y, and Z are independently selected from the group consisting of oxygen, sulfur, and NR a ; \n R 1 , R 2 , R 3 , and R 4  are independently selected from the group consisting of no atom, hydrogen, halogen, C 1-9  alkyl, C 2-9  alkenyl, C 2-9  alkynyl, aryl, heterocyclic, \u2014OH, \u2014OR a , \u2014OR a OR b , \u2014OR a OR b OR c , \u2014OR a (C\u2550O)R b  \u2014O(C\u2550O)R a , \u2014O(C\u2550O)OR a , \u2014O(C\u2550O)NR a R b , cyano, nitro, \u2014CF 3 , \u2014CHF 2 , \u2014CH 2 F, \u2014CHO, \u2014COOH, \u2014COR a , \u2014COOR a , \u2014CONR a R b , \u2014CONHCONR a R b , \u2014NR a R b , \u2014NHCOR a , \u2014NR b COR a , \u2014CSOH, \u2014CSR a , \u2014CSOR a , \u2014CSNR a R b , \u2014CSNHCSNR a R b , \u2014SH, \u2014SR a , \u2014S(C\u2550O)R a , \u2014S(C\u2550O)OR a , \u2014S(C\u2550O)NR a R b ; \n R 5  is selected from the group consisting of hydrogen, C 1-9  alkyl, C 2-9  alkenyl, C 2-9  alkynyl, aryl, heterocyclic, \u2014R a CO, \u2014R a NHCO, and \u2014R a OCO; and \n R 6 , R a , R b , and R c  are independently selected from the group consisting of hydrogen, hydroxyl, amine, C 1-9  alkyl, C 2-9  alkenyl, C 2-9  alkynyl, aryl, and heterocyclic, \n or a crystalline form, hydrate, or pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 94.0
- Lexical Diversity: 1.59091
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15393507', '12604970', '14032739', '13035640', '14088804']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7709224842463165
- 35 USC 102 Novelty (BERT): 0.5603303498070407
- Combined Prediction Score: 0.749863270802389
- Mean Citation Score: 335.78576400000014
- Max Citation Score: 451.7303
- Similarity Product: 352.0151559425473

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test